Our collaboration strategy

Our collaboration strategy

Our mission is pursuing curative gene therapies to give patients and their families more bluebird days. We continue to develop gene therapy technologies and capabilities such as our lentiviral platform to further their application within and beyond our core indications.

We are actively seeking collaborators and licensing opportunities to explore the therapeutic potential of our technologies in new diseases.

what we're looking for

what we're looking for

We are actively seeking collaborators, in- and out-licensing opportunities to fully leverage the therapeutic potential of our platforms. Specific areas of interest include:

• Novel technologies which may enhance key features of hematopoietic stem cell-based lentiviral gene therapy with the goal of improving patient access and experience
• Novel applications of bluebird’s research-stage in vivo lentiviral vector platform
• Clinically-relevant lentiviral vector-based gene therapy programs for severe genetic diseases and other indications with compelling and comprehensive preclinical POC data

contact us

contact us

Are you interested in partnering with bluebird? Please contact us at partner@bluebirdbio.com